BioCentury | Apr 15, 2013
Clinical News

Life Medical regulatory update

...a U.S. patent covering the use of its bioresorbable polymer technology to prevent post-operative adhesions. Life Medical...
BioCentury | Apr 15, 2013
Clinical News

Life Medical regulatory update

...as an addition to a patient's fat cells for injection as a soft tissue filler. Life Medical...
BioCentury | Mar 4, 2013
Company News

IP Group, University of Manchester other news

IP commercialization company IP Group partnered with the university's UMI3 Ltd. technology transfer company to create a proof-of-principle funding facility for the identification and formation of new spinouts from the university. IP Group, which will...
BioCentury | Sep 12, 2011
Company News

Synthemed, Pathfinder deal

...Pathfinder completed its reverse-merger with biomaterials company SyntheMed. The combined company, Pathfinder Cell Therapy Inc...
...in Cambridge, Mass. and will begin trading on the OTCBB shortly (see BioCentury, Jan. 3). SyntheMed Inc....
BioCentury | Apr 11, 2011
Clinical News

Pathfinder Cells endocrine data

...incorporated into the new tissue. Last December, Pathfinder said it would reverse-merge with biomaterials company SyntheMed Inc....
BioCentury | Jan 3, 2011
Company News

Synthemed, Pathfinder deal

...Pathfinder will reverse-merge with biomaterials company SyntheMed in a stock deal. Pathfinder shareholders will own about...
...Cell Therapy Inc. and headquartered in Cambridge, Mass., with SyntheMed shareholders owning the remaining 20%. SyntheMed...
...sole manager and SyntheMed's board, and is subject to approval by SyntheMed and Pathfinder shareholders. SyntheMed Inc....
BioCentury | Oct 5, 2009
Financial News

Synthemed completes private placement of units

SyntheMed Inc. (OTCBB:SYMD), Little Silver, N.J. Business: Dermatology, Drug delivery Date completed: 10/1/09 Type: Private placement of units Raised: $1 million Units: 5 million Price: $0.20 (unit) Shares after offering: 104.7 million Note: Each unit...
BioCentury | Jun 8, 2009
Clinical News

Repel-CV regulatory update

...and other countries, and in the U.S. for use in pediatric patients following open-heart surgery. SyntheMed Inc....
BioCentury | Jul 21, 2008
Company News

Raptor board of directors update

...Raptor Pharmaceutical Corp. (OTCBB:RPTP), Novato, Calif. Business: Neurology, Metabolic, Cancer Appointed: Richard Franklin, chairman of Synthemed Inc. WIR...
BioCentury | Sep 24, 2007
Clinical News

Repel-CV regulatory update

...for the polymer-based bioresorbable adhesion barrier film is under FDA review (see BioCentury, April 2). SyntheMed Inc....
Items per page:
1 - 10 of 58
BioCentury | Apr 15, 2013
Clinical News

Life Medical regulatory update

...a U.S. patent covering the use of its bioresorbable polymer technology to prevent post-operative adhesions. Life Medical...
BioCentury | Apr 15, 2013
Clinical News

Life Medical regulatory update

...as an addition to a patient's fat cells for injection as a soft tissue filler. Life Medical...
BioCentury | Mar 4, 2013
Company News

IP Group, University of Manchester other news

IP commercialization company IP Group partnered with the university's UMI3 Ltd. technology transfer company to create a proof-of-principle funding facility for the identification and formation of new spinouts from the university. IP Group, which will...
BioCentury | Sep 12, 2011
Company News

Synthemed, Pathfinder deal

...Pathfinder completed its reverse-merger with biomaterials company SyntheMed. The combined company, Pathfinder Cell Therapy Inc...
...in Cambridge, Mass. and will begin trading on the OTCBB shortly (see BioCentury, Jan. 3). SyntheMed Inc....
BioCentury | Apr 11, 2011
Clinical News

Pathfinder Cells endocrine data

...incorporated into the new tissue. Last December, Pathfinder said it would reverse-merge with biomaterials company SyntheMed Inc....
BioCentury | Jan 3, 2011
Company News

Synthemed, Pathfinder deal

...Pathfinder will reverse-merge with biomaterials company SyntheMed in a stock deal. Pathfinder shareholders will own about...
...Cell Therapy Inc. and headquartered in Cambridge, Mass., with SyntheMed shareholders owning the remaining 20%. SyntheMed...
...sole manager and SyntheMed's board, and is subject to approval by SyntheMed and Pathfinder shareholders. SyntheMed Inc....
BioCentury | Oct 5, 2009
Financial News

Synthemed completes private placement of units

SyntheMed Inc. (OTCBB:SYMD), Little Silver, N.J. Business: Dermatology, Drug delivery Date completed: 10/1/09 Type: Private placement of units Raised: $1 million Units: 5 million Price: $0.20 (unit) Shares after offering: 104.7 million Note: Each unit...
BioCentury | Jun 8, 2009
Clinical News

Repel-CV regulatory update

...and other countries, and in the U.S. for use in pediatric patients following open-heart surgery. SyntheMed Inc....
BioCentury | Jul 21, 2008
Company News

Raptor board of directors update

...Raptor Pharmaceutical Corp. (OTCBB:RPTP), Novato, Calif. Business: Neurology, Metabolic, Cancer Appointed: Richard Franklin, chairman of Synthemed Inc. WIR...
BioCentury | Sep 24, 2007
Clinical News

Repel-CV regulatory update

...for the polymer-based bioresorbable adhesion barrier film is under FDA review (see BioCentury, April 2). SyntheMed Inc....
Items per page:
1 - 10 of 58